Company: AZN
Filing Date: 2025-10-06
Form Type: 6-K
Source: 0001654954-25-011461
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-10-06
Form: 6-K
Chunk 6
---
 World Health Organization. Breast Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer Accessed October 2025.

5. American Cancer Society. Triple-Negative Breast Cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html . Accessed October 2025.

6. Martinez et al. Contribution of Clinical and Socioeconomic Factors to Differences in Breast Cancer Subtype and Mortality Between Hispanic and Non-Hispanic White Women. Breast Cancer Res Treat . 2017; 166(1):185-193

7. Vargas et al. Risk Factors for Triple-Negative Breast Cancer Among Latina Women. Cancer Epidemiol Biomarkers Prev (2019) 28 (11): 1771-1783.

8. National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer Subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html . Accessed October 2025.

9. Sharma P, et al. Biology and Management of Patients with Triple-Negative Breast Cancer. Oncologist . 2016; 21(9): 1050-62. 10.1634/theoncologist.2016.0067.

10. Cortes J, et al. Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med . 2022;387:217-226.

11. Geurts V, et al. Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches. Curr Treat Options Oncol . 2023; 24:628-643.

12. Rossi V, et al. Sacituzumab Govitecan in Triple-Negative Breast Cancer: from Bench to Bedside, and Back Front Immunol . 2024 Aug;15: 1447280.

13. Lin H, et al. Significantly upregulated TACSTD2 and Cyclin D1 Correlate with Poor Prognosis of Invasive Ductal Breast Cancer. Exp Mol Pathol . 2013:94(1): 73-78.

14. Goldenberg D, et al. The Emergence of Trophoblast Cell-Surface Antigen 2 (TROP-2) as a Novel Cancer Target. Oncotarget. 2018;9(48): 289